Physical activity program for CLL patients on ibrutinib
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether a personalized physical activity program can improve quality of life for people with CLL who are starting the drug ibrutinib. You would wear an activity watch and use a digital tool to track your activity over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are starting or have recently started (within 8 days) the drug ibrutinib for CLL
- You are willing to follow a personalized physical activity program
- You have a smartphone, laptop, or tablet and internet access at home
- You agree to wear a study watch 24/7 for the entire study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with chronic lymphocytic leukemia (CLL)—a blood cancer—who are starting treatment with two drugs called ibrutinib and venetoclax together for a set period of time. Researchers want to understand how well this treatment works and how it affects patients' daily lives in real-world settings, rather than in a controlled lab environment.
This trial studies whether taking ibrutinib in a less continuous (“intermittent”) schedule can keep your chronic lymphocytic leukemia (CLL) under control. It’s for people who have already received ibrutinib for at least 6 months and had a good early response, aiming to reduce treatment intensity while tracking safety and cancer control.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This study tests whether using a connected blood pressure monitor at home can help manage blood pressure in people starting a BTK inhibitor (a type of targeted therapy for blood cancers). Participation may help detect and manage high blood pressure early, which is a known side effect of these drugs.
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
This trial tests a community-based physical activity program designed for people who have had cancer or care for someone who has. The goal is to see if it can help improve health and well-being for those not currently on active treatment.
Hear when a new Leukemia, Lymphocytic, Chronic, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.